Organovo Holdings, Inc. — Form 10-Q Summary
Period: Quarter and six months ended June 30, 2012. The filing identifies the registrant as Organovo Holdings, Inc.; this differs from the company name in the request metadata.
Business context and reporting period
Organovo was a development-stage company developing and commercializing a platform for producing 3D human tissues for drug discovery, biological research, and potential therapeutic applications. It had not generated significant revenue from its planned principal operations. On February 8, 2012, Organovo, Inc. merged into a wholly owned subsidiary of Organovo Holdings. The transaction was accounted for as a reverse merger and recapitalization; the statements principally reflect Organovo, Inc.’s historical results before the merger.
Financial results and position
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Revenue | $258,975 | $378,975 | $173,375 quarterly; $374,664 six-month |
| Operating loss | $1,449,659 | $2,778,789 | $473,637 quarterly; $965,090 six-month |
| Net loss | $35,385,142 | $72,465,723 | $532,480 quarterly; $1,078,565 six-month |
| Operating cash used | Not presented for quarter | $5,414,181 | $609,342 six-month |
- All revenue in the 2012 periods came from collaborations; there was no product or grant revenue. Six-month 2012 product revenue was zero, although cost of product revenue was $50,584.
- At June 30, cash and cash equivalents were $8,469,312; current assets were $9,201,046 and current liabilities $889,006, yielding working capital of $8,312,040. Restricted cash was $88,290.
- Total liabilities were $81,466,994, including $80,577,988 of warrant liabilities. The company reported a stockholders’ deficit of $71,757,582 and accumulated deficit of $79,157,279.
- No convertible notes payable remained at June 30. A $1.5 million convertible-note balance and accrued interest converted into shares in connection with the merger; another note and interest were repaid. The filing reports no ending debt balance beyond the warrant liability and other current obligations.
- The 2012 private placements generated $13,722,600 gross proceeds from common stock and warrants; net proceeds were $11,593,066. Financing cash flow for the six months was $13,712,353.
Changes versus prior comparable periods
- Quarterly revenue rose about 49% year over year, mainly from collaborative research revenue. Six-month revenue was nearly flat, up about 1%, as higher collaboration revenue was offset by the absence of prior-year grant and product revenue.
- Six-month operating expenses rose to $3,157,764 from $1,289,170, driven by expanded staffing, research activity, facilities, and costs of operating as a public company. Research and development expense increased 69% to $1,199,855; selling, general and administrative expense increased to $1,957,909 from $579,440.
- Net loss increased sharply, primarily because of noncash warrant accounting: six-month expenses included $19,019,422 for warrant fair value in excess of issuance proceeds and a $47,442,994 increase in warrant fair value. The quarterly change in warrant fair value was $33,937,175.
- Cash increased from $339,607 at December 31, 2011 to $8,469,312 at June 30, 2012, largely following the private placements. Operating cash use also increased substantially from the prior-year six-month period.
Outlook, risks, and unusual items
- Management said cash on hand, together with expected receipts from grants and collaborative agreements, should fund planned operations for at least the next 12 months. The company also stated that continued operations and further development depend on raising additional capital and generating collaboration or commercial revenue; financing availability and terms were not assured.
- The large warrant liability resulted from warrants with down-round price protection and Level 3 fair-value estimates. Management warned that changes in share price, volatility, and other valuation assumptions could cause significant quarter-to-quarter changes in reported earnings.
- Potential financing could dilute shareholders or impose debt covenants. At June 30, 24,111,932 warrants were outstanding at a $1.00 exercise price; the filing also described a 6,553,986-share authorization under the 2012 equity plan.
- A new 48-month facility lease began with base rent of approximately $38,800 per month and 3% annual increases. Disclosed future minimum rent payments totaled $1,915,385.
- After quarter-end, the company issued 950,000 time-vesting restricted stock units and 200,000 performance-based restricted stock units to senior management.
- The company reported no ongoing legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- How much of the reported loss reflects noncash warrant remeasurement, and what assumptions drive the $80.6 million warrant liability?
- Whether collaboration revenue, customer receipts, and commercial arrangements can grow enough to support operations after the stated 12-month cash horizon.
- The company’s expected cash burn and available liquidity after the first-half 2012 financing proceeds.
- The potential dilution from outstanding warrants, options, equity-plan shares, and subsequent restricted stock unit awards.
- Whether the merger, reverse-merger accounting, and company-name discrepancy in the request metadata are correctly reflected in the investor’s source records.